Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04950114 · ClinicalTrials.gov registry record · Phase 2
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
A Phase 2 study, sponsored by Goldfinch Bio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT04950114 is a Phase 2 study that was terminated before completion, run by Goldfinch Bio. The registered enrollment target is 31 participants.
The verdict
NCT04950114, a Phase 2 study, was terminated before completion, sponsored by Goldfinch Bio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is an open-label Phase 2 study evaluating the long term safety and tolerability of GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD)
Interventions
- DRUG GFB-887
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-07-27 |
| Est. Completion | 2022-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04950114
The ClinicalTrials.gov registry entry for NCT04950114 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Goldfinch Bio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GFB-887 is the first listed.
NCT04950114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04950114 about?
NCT04950114 is a clinical study titled "An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases". This is an open-label Phase 2 study evaluating the long term safety and tolerability of GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD)
What is the current status of trial NCT04950114?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2021-07-27. Estimated completion is 2022-11-02.
What interventions are being tested in trial NCT04950114?
The interventions under investigation include: GFB-887 (DRUG).
Who is sponsoring clinical trial NCT04950114?
This trial is sponsored by Goldfinch Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.